Multivalent RNA CAR-T Cell for Malignant Glioma

Explore the cutting-edge research on Multivalent RNA CAR-T cell therapy for malignant glioma in this 52-minute webinar presented by Prof. Denis Migliorini. Delve into the challenges of applying CAR-T cell therapy to solid tumors, particularly glioblastoma, and discover the innovative "à-la-carte" strategy targeting multiple GBM antigens. Learn about the development of transiently expressed RNA CAR-T cells, designed to reduce side effects while allowing for multiple infusions. Gain insights into the phage display screening process for generating new scFv against GBM-associated targets, and understand the cytotoxic activity selection process using patient-derived cell lines. Examine the use of triple reporter Jurkat cell lines to demonstrate sustained CAR expression, and explore the promising results from orthotopic allogeneic tumor models in NSG mice. Uncover the potential of RNA CARTs as a novel manufacturing platform for glioblastoma treatment, offering hope for improved therapeutic outcomes in this challenging field of oncology.

Multivalent RNA CAR-T cell for malignant glioma